Fukada Ippei, Ikeda Hiroyoshi, Yamaguchi Kazushige, Okabe Michio, Tsuruta Atsushi, Morimoto Yoshinori, Kawamoto Kazuyuki, Sano Kaoru, Paku Tebun, Imai Shiro, Yoshida Yasuo, Ito Tadashi, Ogasahara Keizo
Dept. of Surgery, Kurashiki Central Hospital.
Gan To Kagaku Ryoho. 2009 Oct;36(10):1733-6.
The patient was a 54-year-old male. In July 2004, he underwent resection of the pancreatic body tail region to treat pancreatic body tail cancer. On histopathological examination, the stump of the extirpated specimen was positive for tumor cells. After surgery, 10 courses of therapy with gemcitabine hydrochloride(GEM, 1, 000 mg/m(2), 3-week administration followed by 1-week discontinuation)were performed, and follow-up was continued. In February 2006, local relapse was detected. Chemotherapy with GEM was administered for 1 year and 9 months. However, in November 2007, an increase in the recurrent lesion size and right lung metastasis were noted. The regimen was switched to combination therapy with S-1 and GEM(S-1 60 mg/m(2) day, continuous administration on days 1 to 14 and 2-week discontinuation; and GEM 1, 000 mg/ m(2), administered on days 8 and 15). After the end of the 11th course, PET-CT revealed the disappearance of FDG accumulation in the recurrent and metastatic lesion sites. During the treatment period, there were no grade 3 or higher adverse reactions. The patient is being treated at the outpatient clinic (as of January 2009).
该患者为一名54岁男性。2004年7月，他接受了胰体尾区域切除术以治疗胰体尾癌。组织病理学检查显示，切除标本的残端有肿瘤细胞阳性。术后，进行了10个疗程的盐酸吉西他滨（GEM，1000mg/m²，每3周给药1次，随后停药1周）治疗，并持续随访。2006年2月，检测到局部复发。给予GEM化疗1年9个月。然而，2007年11月，发现复发病灶增大并出现右肺转移。治疗方案改为S-1与GEM联合治疗（S-1 60mg/m² 每日，第1至14天持续给药，停药2周；GEM 1000mg/m²，在第8天和第15天给药）。第11个疗程结束后，PET-CT显示复发和转移病灶部位的FDG摄取消失。治疗期间，未出现3级或更高等级的不良反应。该患者目前在门诊接受治疗（截至2009年1月）。
